Status:
COMPLETED
Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly
Lead Sponsor:
GlaxoSmithKline
Conditions:
Influenza
Eligibility:
All Genders
67+ years
Phase:
PHASE2
Brief Summary
Since influenza vaccines are normally administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of adjuvanted influenza vaccine need ...
Eligibility Criteria
Inclusion
- The subjects must be healthy elderly \>/= 67 years and previously vaccinated with Fluarix or the adjuvanted vaccine.
Exclusion
- Subjects will be excluded if they take/have taken chronically high doses of immunosuppressants or other immunemodifying drugs within six months before vaccination, or immunoglobulins or blood products within three months before vaccination, or any investigational product within 30 days before vaccination, have a history of influenza infection since previous vaccination, or if subjects have acute or chronic clinically significant disease or an immunosuppressive/deficient condition, or have contra-indications to influenza vaccination
Key Trial Info
Start Date :
October 16 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 14 2006
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT00386113
Start Date
October 16 2006
End Date
November 14 2006
Last Update
February 26 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Ghent, Belgium, 9000